Aviva
WST icon

Aviva’s West Pharmaceutical WST Stock Holding History

Aviva’s Portfolio WST Stock Details WST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$22.8M Buy
63,477
+91
+0.1% +$27.8K 0.03% 395
2026
Q1 		$15.9M Buy
63,386
+1,700
+3% +$423K 0.03% 448
2025
Q4 		$17M Buy
61,686
+3,109
+5% +$850K 0.03% 435
2025
Q3 		$15.4M Buy
58,577
+3,012
+5% +$732K 0.03% 443
2025
Q2 		$12.2M Buy
55,565
+2,858
+5% +$611K 0.03% 481
2025
Q1 		$11.8M Buy
52,707
+7,091
+16% +$1.95M 0.03% 428
2024
Q4 		$14.9M Sell
45,616
-55,024
-55% -$17.3M 0.04% 366
2024
Q3 		$30.2M Buy
100,640
+2,589
+3% +$793K 0.08% 288
2024
Q2 		$32.3M Buy
98,051
+38,012
+63% +$13.4M 0.09% 261
2024
Q1 		$23.8M Buy
60,039
+13,265
+28% +$4.91M 0.08% 297
2023
Q4 		$16.5M Buy
46,774
+6,633
+17% +$2.35M 0.06% 368
2023
Q3 		$15.1M Buy
40,141
+6,995
+21% +$2.71M 0.06% 360
2023
Q2 		$12.7M Sell
33,146
-119,200
-78% -$42.6M 0.05% 392
2023
Q1 		$52.8M Buy
152,346
+11,665
+8% +$3.41M 0.24% 81
2022
Q4 		$33.1M Buy
140,681
+25,094
+22% +$5.95M 0.16% 151
2022
Q3 		$28.4M Buy
115,587
+14,923
+15% +$4.55M 0.16% 141
2022
Q2 		$30.4M Buy
100,664
+52,653
+110% +$17.1M 0.16% 136
2022
Q1 		$19.7M Buy
48,011
+16,337
+52% +$6.4M 0.1% 244
2021
Q4 		$14.9M Sell
31,674
-2,689
-8% -$1.16M 0.06% 299
2021
Q3 		$14.6M Buy
34,363
+8,706
+34% +$3.67M 0.07% 291
2021
Q2 		$9.21M Sell
25,657
-3,434
-12% -$1.13M 0.04% 414
2021
Q1 		$8.2M Sell
29,091
-717
-2% -$205K 0.04% 390
2020
Q4 		$8.45M Sell
29,808
-2,079
-7% -$583K 0.04% 364
2020
Q3 		$8.77M Buy
31,887
+21,511
+207% +$5.69M 0.05% 307
2020
Q2 		$2.36M Sell
10,376
-14,499
-58% -$2.85M 0.01% 608
2020
Q1 		$3.79M Buy
24,875
+12,230
+97% +$1.88M 0.03% 497
2019
Q4 		$1.9M Buy
+12,645
New +$1.84M 0.01% 773
2018
Q3 		– Sell
-44,143
Closed -$4.38M – 756
2018
Q2 		$4.38M Buy
+44,143
New +$4.06M 0.03% 562

Other funds holding WST

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
GIM
Generation Investment Management London, United Kingdom $10.3B AUM 4.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Aviva's WST Position: Q2 2026 in Review

Aviva increased its West Pharmaceutical (WST) stake by 0.14% in Q2 2026, buying an estimated $27.8K and bringing the position to 63,477 shares worth $22.8M. The position accounts for 0.03% of the portfolio, ranked #395.

Aviva first reported a position in WST in Q2 2018 and has held it in 28 quarters since. The position peaked at $52.8M in Q1 2023. 830 funds tracked by Wall St. Rank hold WST as of Q2 2026.

  • Aviva held 63,477 shares of West Pharmaceutical worth $22.8M as of Q2 2026.
  • Aviva bought 91 West Pharmaceutical shares in Q2 2026, an estimated $27.8K.
  • West Pharmaceutical made up 0.03% of Aviva's portfolio in Q2 2026, its #395 holding.
  • Aviva first reported a position in West Pharmaceutical in Q2 2018 and has held it in 28 quarters since.
  • Aviva's West Pharmaceutical position peaked at $52.8M in Q1 2023.
  • 830 funds tracked by Wall St. Rank held West Pharmaceutical as of Q2 2026.

Based on Aviva's 13F filing for Q2 2026, filed 13 Aug 2026.